Omics and drug response

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 475-502

  Meyer, Urs A ^a   Zanger, Ulrich M ^b   Schwab, Matthias ^b,c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

biomarkers; genomic medicine; genotype phenotype; personalized medicine; pharmacogenetics; pharmacogenomics

Indexed keywords

ABACAVIR; ACENOCOUMAROL; ALKYLATING AGENT; ALPHA INTERFERON; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAMAZEPINE; CARMUSTINE; CISPLATIN; DASATINIB; DOXORUBICIN; FLUCLOXACILLIN; GALACTOSAMINE; IMATINIB; IRINOTECAN; LUMIRACOXIB; MARAVIROC; METFORMIN; METHOTREXATE; NILOTINIB; PARACETAMOL; PEGINTERFERON ALPHA; PHENPROCOUMON; SIMVASTATIN; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VEMURAFENIB; WARFARIN; XIMELAGATRAN;

ALLERGIC REACTION; ARTERIAL THROMBOEMBOLISM; BLEEDING; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG CHOICE; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GASTROINTESTINAL STROMAL TUMOR; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; GLIOMA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; LIVER CANCER; LIVER TOXICITY; LYMPHOMA; MEDICAL DECISION MAKING; MELANOMA; METABOLOMICS; MICROARRAY ANALYSIS; MUSCLE DISEASE; MYOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY CANCER; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STENT THROMBOSIS; STEVENS JOHNSON SYNDROME; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TOXICITY TESTING; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 84872248328     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010510-100502     Document Type: Review

References (194)

1. Spear BB, Heath-Chiozzi M, Huff J. 2001. Clinical application of pharmacogenetics. Trends Mol. Med. 7:201-4
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. 2004. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. Br. Med. J. 329:15-19
3. Meyer UA. 2004. Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5:669-76
4. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, et al. 2006. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145:749-57
5. Daly AK. 2010. Pharmacogenetics and human genetic polymorphisms. Biochem. J. 429:435-49
6. Pirmohamed M. 2011. Pharmacogenetics: past, present and future. Drug Discov. Today 16:852-61
7. Scott SA. 2011. Personalizing medicine with clinical pharmacogenetics. Genet. Med. 13:987-95
8. Sim SC, Ingelman-Sundberg M. 2011. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol. Sci. 32:72-81
9. Wang L, McLeod HL, Weinshilboum RM. 2011. Genomics and drug response. N. Engl. J. Med. 364:1144-53
10. Feero WG, Guttmacher AE, Collins FS. 2010. Genomicmedicine-an updated primer. N. Engl. J.Med. 362:2001-11
11. Meyer UA. 2012. Personalized medicine: a personal view. Clin. Pharmacol. Ther. 91:373-75
12. Natl. Res.Counc. 2011. Committee on a framework for developing a new taxonomy of disease. In Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: Natl. Acad. Press
13. Topol E. 2012. The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care. New York: Basic Books
14. Berg JS,Khoury MJ, Evans JP. 2011. Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet. Med. 13:499-504
15. Gonzaga-Jauregui C, Lupski JR, Gibbs RA. 2012. Human genome sequencing in health and disease. Annu. Rev. Med. 63:35-61
16. Human genome: Genomes by the thousand. 2010. Nature 467:1026-27
17. Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, et al. 2010. Clinical assessment incorporating a personal genome. Lancet 375:1525-35
18. Dewey FE, Chen R, Cordero SP, Ormond KE, Caleshu C, et al. 2011. Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genet. 7:e1002280
19. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HYK, et al. 2012. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148:1293-307
20. Mardis ER. 2010. The $1,000 genome, the $100,000 analysis? Genome Med. 2:84
21. Thorisson GA, Stein LD. 2003. The SNP Consortium website: past, present and future. Nucleic Acids Res. 31:124-27
22. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, et al. 2010. Integrating common and rare genetic variation in diverse human populations. Nature 467:52-58
23. -1000 Genomes Proj. Consort. 2010. A map of human genome variation from population-scale sequencing. Nature 467:1061-73
24. MacArthur DG, Balasubramanian S, Frankish A, Huang N, Morris J, et al. 2012. A systematic survey of loss-of-function variants in human protein-coding genes. Science 335:823-28
25. The Int.Hum.Genome Seq. Consort. 2004. Finishing the euchromatic sequence of the human genome. Nature 431:931-45
26. Houle D, Govindaraju DR, Omholt S. 2010. Phenomics: the next challenge. Nat. Rev. Genet. 11:855-66
27. Rappaport SM. 2011. Implications of the exposome for exposure science. Nucleic Acids Res. 21:5-9
28. Ramsey LB, Bruun GH, Yang W, Trevi ̃ no LR, Vattathil S, et al. 2012. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 22:1-8
29. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, et al. 2010. International network of cancer genome projects. Nature 464:993-98
30. Cancer Genome Atlas Res. Netw. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-68
31. Puente XS, Pinyol M, Quesada V, Conde L, Ord? ̃ nez GR, et al. 2011. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101-5
32. Cancer Genome Atlas Res. Netw. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:609-15
33. Zhang S,Huang W-C, Li P, Guo H, Poh S-B, et al. 2011. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 17:461-69
34. Daly AK, Day CP. 2012. Genetic association studies in drug-induced liver injury. Drug Metab. Rev. 44:116-26
35. Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, et al. 2011. Genome-wide association study identifies HLA-A?3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20:1034-41
36. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavici ute D, et al. 2011. HLA-A?3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364:1134-43
37. Shen Y, Nicoletti P, Floratos A, Pirmohamed M, Molokhia M, et al. 2012. Genome-wide association study of serious blistering skin rash caused by drugs. Pharmacogenomics J. 12:96-104
38. Link E, Parish S, Armitage J, Bowman L, Heath S, et al. 2008. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359:789-99
39. Niemi M, Pasanen MK, Neuvonen PJ. 2011. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63:157-81
40. Shuldiner AR,O'Connell JR, Bliden KP,Gandhi A, Ryan K, et al. 2009. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-57
41. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401
42. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-αand ribavirin therapy. Nat. Genet. 41:1100-4
43. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. 2009. Genome-wide association of IL28B with response to pegylated interferon- αand ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105-9
44. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, et al. 2008. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-27
45. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, et al. 2009. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5:e1000433
46. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RHN, et al. 2009. A genomewide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 18:3758-68
47. Teichert M, Eijgelsheim M, Uitterlinden AG, Buhre PN, Hofman A, et al. 2011. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Pharmacogenet. Genomics 21:26-34
48. Zhou K, Bellenguez C, Spencer CCA, Bennett AJ, Coleman RL, et al. 2011. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 43:117-20
49. Kiyotani K, Mushiroda T, Tsunoda T, Morizono T, Hosono N, et al. 2012. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum. Mol. Genet. 21:1665-72
50. Trevi ̃ no LR, Shimasaki N, Yang W, Panetta JC, Cheng C, et al. 2009. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27:5972-78
51. Visscher PM, Brown MA, McCarthy MI, Yang J. 2012. Five years of GWAS discovery. Am. J. Hum. Genet. 90:7-24
52. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al. 2009. Finding the missing heritability of complex diseases. Nature 461:747-53
53. Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. 2012. The predictive capacity of personal genome sequencing. Sci. Transl. Med. 4:133ra58
54. Zuk O, Hechter E, Sunyaev SR, Lander ES. 2012. The mystery of missing heritability: Genetic interactions create phantom heritability. Proc. Natl. Acad. Sci. USA 109:1193-98
55. Daly AK. 2012. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacol. Toxicol. 52:21-35
56. Daly AK. 2010. Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11:241-46
57. Gamazon ER, Skol AD, Perera MA. 2012. The limits of genome-wide methods for pharmacogenomic testing. Pharmacogenet. Genomics 22:261-72
58. Esteller M. 2008. Epigenetics in cancer. N. Engl. J. Med. 358:1148-59
59. Dawson MA, Kouzarides T. 2012. Cancer epigenetics: from mechanism to therapy. Cell 150:12-27
60. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, et al. 2010. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol. 6:39-51
61. Rodruez-Paredes M, Esteller M. 2011. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17:330-39
62. Sandoval J, Esteller M. 2012. Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 22:50-55
63. Kacevska M, Ivanov M, Ingelman-Sundberg M. 2011. Perspectives on epigenetics and its relevance to adverse drug reactions. Clin. Pharmacol. Ther. 89:902-7
64. Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, et al. 2011. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med. 3:82
65. Rakyan VK, Down TA, Balding DJ, Beck S. 2011. Epigenome-wide association studies for common human diseases. Nat. Rev. Genet. 12:529-41
66. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, et al. 2005. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. USA 102:10604-9
67. Lee RC, Feinbaum RL, Ambros V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843-54
68. Mendell JT, Olson EN. 2012. MicroRNAs in stress signaling and human disease. Cell 148:1172-87
69. Nair VS,Maeda LS, Ioannidis JPA. 2012. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J. Natl. Cancer Inst. 104:528-40
70. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. 2009. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361:1437-47
71. ZhangW,Dolan ME. 2010. The emerging role ofmicroRNAs in drug responses. Curr. Opin.Mol. Ther. 12:695-702
72. Rukov JL, Shomron N. 2011. MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol. Med. 17:412-23
73. Koturbash I, Beland FA, Pogribny IP. 2012. Role of microRNAs in the regulation of drug metabolizing and transporting genes and the response to environmental toxicants. Expert Opin. Drug Metab. Toxicol. 8:597-606
74. Mishra PJ,Humeniuk R,Mishra PJ, Longo-Sorbello GSA, Banerjee D, et al. 2007. AmiR-24microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl. Acad. Sci. USA 104:13513-18
75. Sun W, Li Y-SJ, Huang H-D, Shyy JY-J, Chien S. 2010. microRNA: a master regulator of cellular processes for bioengineering systems. Annu. Rev. Biomed. Eng. 12:1-27
76. Rhodes DR, Chinnaiyan AM. 2005. Integrative analysis of the cancer transcriptome. Nat. Genet. 37:S31-37
77. Yeoh E-J, Ross ME, Shurtleff SA,Williams WK, Patel D, et al. 2002. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-43
78. Holleman A,Cheok MH, den Boer ML, Yang W, Veerman AJP, et al. 2004. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J.Med. 351:533-42
79. Klinakis A, Lobry C, Abdel-Wahab O, Oh P,Haeno H, et al. 2011. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473:230-33
80. Cronin M, Sangli C, Liu M-L, Pho M, Dutta D, et al. 2007. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 53:1084-91
81. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, et al. 2010. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann. Oncol. 21:717-22
82. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, et al. 2005. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 23:3526-35
83. Dyrskj? L, Zieger K, Real FX, Malats N, Carrato A, et al. 2007. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin. Cancer Res. 13:3545-51
84. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu Y-M, et al. 2011. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3:111ra121
85. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-7
86. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. 2012. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-75
87. Dill MT, Duong FHT, Vogt JE, Bibert S, Bochud P-Y, et al. 2011. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140:1021-31
88. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, et al. 2008. Alternative isoform regulation in human tissue transcriptomes. Nature 456:470-76
89. Wang G-S, Cooper TA. 2007. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat. Rev. Genet. 8:749-61
90. SadeeW,Wang D, Papp AC, Pinsonneault JK, Smith RM, et al. 2011. Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin. Pharmacol. Ther. 89:355-65
91. Barrie ES, Smith RM, Sanford JC, Sadee W. 2012. mRNA transcript diversity creates new opportunities for pharmacological intervention. Mol. Pharmacol. 81:620-30
92. Wang Z, Gerstein M, Snyder M. 2009. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10:57-63
93. Ozsolak F, Milos PM. 2011. RNA sequencing: advances, challenges and opportunities. Nat. Rev. Genet. 12:87-98
94. Montgomery SB, Sammeth M, Gutierrez-Arcelus M, Lach RP, Ingle C, et al. 2010. Transcriptome genetics using second generation sequencing in a Caucasian population. Nature 464:773-77
95. Manolio TA. 2010. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363:166-76
96. Majewski J, Pastinen T. 2011. The study of eQTL variations by RNA-seq: from SNPs to phenotypes. Trends Genet. 27:72-79
97. Montgomery SB, Lappalainen T, Gutierrez-Arcelus M, Dermitzakis ET. 2011. Rare and common regulatory variation in population-scale sequenced human genomes. PLoS Genet. 7:e1002144
98. Cox J, Mann M. 2011. Quantitative, high-resolution proteomics for data-driven systems biology. Annu. Rev. Biochem. 80:273-99
99. Yates JR, Ruse CI, Nakorchevsky A. 2009. Proteomics by mass spectrometry: approaches, advances, and applications. Annu. Rev. Biomed. Eng. 11:49-79
100. Domon B, Aebersold R. 2010. Options and considerations when selecting a quantitative proteomics strategy. Nat. Biotechnol. 28:710-21
101. Bensimon A, Heck AJR, Aebersold R. 2012. Mass spectrometry-based proteomics and network biology. Annu. Rev. Biochem. 81:379-405
102. Rhea JM, Molinaro RJ. 2011. Cancer biomarkers: surviving the journey from bench to bedside. MLO Med. Lab. Obs. 43:10-12, 16, 18; quiz 20, 22
103. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. 2012. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9:16-32
104. Antoine DJ, Jenkins RE, Dear JW,Williams DP, McGill MR, et al. 2012. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J. Hepatol. 56:1070-79
105. Lamond AI, UhlenM,Horning S, Makarov A, Robinson CV, et al. 2012. Advancing cell biology through proteomics in space and time (PROSPECTS). Mol. Cell. Proteomics 11:O112.017731
106. Hanash S. 2004. Building a foundation for the human proteome: the role of the Human Proteome Organization. J. Proteome Res. 3:197-99
107. Johnson CH, Gonzalez FJ. 2012. Challenges and opportunities of metabolomics. J. Cell. Physiol. 227:2975-81
108. Nicholson JK, Everett JR, Lindon JC. 2012. Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy. Expert Opin. Drug Metab. Toxicol. 8:135-39
109. Nicholson JK, Lindon JC. 2008. Systems biology: Metabonomics. Nature 455:1054-56
110. Chung Y-L, Griffiths JR. 2007. Using metabolomics to monitor anticancer drugs. Ernst Schering Found. Symp. Proc. 4:55-78
111. Lindon JC, Nicholson JK. 2008. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu. Rev. Anal. Chem. 1:45-69
112. O'Connell TM, Watkins PB. 2010. The application of metabonomics to predict drug-induced liver injury. Clin. Pharmacol. Ther. 88:394-99
113. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, et al. 2006. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073-77
114. Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, et al. 2010. Use of pharmacometabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin. Pharmacol. Ther. 88:45-51
115. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. 2008. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 48:653-83
116. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, et al. 2011. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomicsinformed pharmacogenomics. Clin. Pharmacol. Ther. 89:97-104
117. Suhre K, Shin S-Y, Petersen A-K,Mohney RP, Meredith D, et al. 2011. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477:54-60
118. Suhre K, Wallaschofski H, Raffler J, Friedrich N, Haring R, et al. 2011. A genome-wide association study of metabolic traits in human urine. Nat. Genet. 43:565-69
119. Kitano H. 2007. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 6:202-10
120. Kohl P, Crampin EJ, Quinn TA, Noble D. 2010. Systems biology: an approach. Clin. Pharmacol. Ther. 88:25-33
121. del Sol A, Balling R, Hood L, Galas D. 2010. Diseases as network perturbations. Curr. Opin. Biotechnol. 21:566-71
122. Inouye M, Kettunen J, Soininen P, Silander K, Ripatti S, et al. 2010. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol. Syst. Biol. 6:441
123. Ramsey SA, Gold ES, Aderem A. 2010. A systems biology approach to understanding atherosclerosis. EMBO Mol. Med. 2:79-89
124. Bassingthwaighte J, Hunter P, Noble D. 2009. The Cardiac Physiome: perspectives for the future. Exp. Physiol. 94:597-605
125. Holzhutter H-G, Drasdo D, Preusser T, Lippert J, Henney AM. 2012. The virtual liver: a multidisciplinary, multilevel challenge for systems biology. Wiley Interdiscip. Rev. Syst. Biol. Med. 4:221-35
126. Hunter P, Coveney PV, de Bono B, Diaz V, Fenner J, et al. 2010. A vision and strategy for the virtual physiological human in 2010 and beyond. Philos. Trans. R. Soc. A 368:2595-614
127. Rodriguez B, Burrage K, Gavaghan D, Grau V, Kohl P, et al. 2010. The systems biology approach to drug development: application to toxicity assessment of cardiac drugs. Clin. Pharmacol. Ther. 88:130-34
128. Rostami-Hodjegan A, Tucker GT. 2007. Simulation and prediction of in vivo drugmetabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6:140-48
129. Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, et al. 2011. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front. Physiol. 2:4
130. Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. 2009. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin. Pharmacol. Ther. 86:634-43
131. TanY-M,Clewell H, Campbell J, Andersen M. 2011. Evaluating pharmacokinetic and pharmacodynamic interactions with computational models in supporting cumulative risk assessment. Int. J. Environ. Res. Public Health 8:1613-30
132. Hopkins AL. 2008. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4:682-90
133. Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL. 2006. Global mapping of pharmacological space. Nat. Biotechnol. 24:805-15
134. Yildirim MA, Goh K-I, Cusick ME, Barab?si A-L, Vidal M. 2007. Drug-target network. Nat. Biotechnol. 25:1119-26
135. Jensen PB, Jensen LJ, Brunak S. 2012. Mining electronic health records: towards better research applications and clinical care. Nat. Rev. Genet. 13:395-405
136. Scott CT, Caulfield T, Borgelt E, Illes J. 2012. Personal medicine-the new banking crisis. Nat. Biotechnol. 30:141-47
137. Ritchie MD, Denny JC, Crawford DC, Ramirez AH, Weiner JB, et al. 2010. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am. J. Hum. Genet. 86:560-72
138. Delaney JT,Ramirez AH, Bowton E, Pulley JM, Basford MA, et al. 2012. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin. Pharmacol. Ther. 91:257-63
139. Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, et al. 2012. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 13:407-18
140. Roden DM, Xu H, Denny JC,Wilke RA. 2012. Electronic medical records as a tool in clinical pharmacology: opportunities and challenges. Clin. Pharmacol. Ther. 91:1083-86
141. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, et al. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69:89-95
142. US Food Drug Admin. 2010. Guidance for industry: qualification process for drug development tools. Oct. 2010, US Food Drug Admin., Silver Spring, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM230597.pdf
143. Eur. Med. Agency. 2012. Qualification of novel methodologies for medicine development. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/ document-listing/document-listing-000319.jsp&mid=WC0b01ac0580022bb0
144. US Food Drug Admin. 2012. Table of pharmacogenomic biomarkers in drug labels. US Food Drug Admin., Aug. 3. http://www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/ucm083378.htm
145. Swen JJ, Nijenhuis M, de Boer A, Grandia L,Maitland-van der Zee AH, et al. 2011. Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89:662-73
146. Blay J-Y, von Mehren M. 2011. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin. Oncol. 38(Suppl. 1):S3-9
147. Druker BJ. 2006. Circumventing resistance to kinase-inhibitor therapy. N. Engl. J. Med. 354:2594-96
148. McCormack PL, Keam SJ. 2011. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs 71:1771-95
149. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, et al. 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366:707-14
150. Perry CM. 2010. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Drugs 70:1189-213
151. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, et al. 2011. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90:625-29
152. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot J-S, et al. 2011. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90:328-32
153. Johnson JA, Roden DM, Lesko LJ, Ashley E, Klein TE, et al. 2012. Clopidogrel: a case for indicationspecific pharmacogenetics. Clin. Pharmacol. Ther. 91:774-76
154. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, et al. 2012. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91:321-26
155. Argiles G, Dienstmann R, Elez E, Tabernero J. 2012. Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol. 8:373-89
156. Garrett CR, Eng C. 2011. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin. Biol. Ther. 11:937-49
157. Pal SK, Figlin RA, Reckamp K. 2010. Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol. Cancer Ther. 9:1931-44
158. CurranMP. 2012. Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs 72:99-107
159. Croxtall JD, McKeage K. 2011. Fulvestrant: a review of its use in the management of hormone receptorpositive metastatic breast cancer in postmenopausal women. Drugs 71:363-80
160. Jordan VC. 2008. Tamoxifen: catalyst for the change to targeted therapy. Eur. J. Cancer 44:30-38
161. Deeks ED, Scott LJ. 2009. Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs 69:889-918
162. Barnadas A, Est?vez LG, Lluch-Hern?ndez A, Rodriguez-Lescure A, Rodriguez-Sanchez C, Sanchez-Rovira P. 2011. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer. Adv. Ther. 28:1045-58
163. McDonagh EM, Thorn CF, Bautista JM, Youngster I, Altman RB, Klein TE. 2012. PharmGKB summary: very important pharmacogene information for G6PD. Pharmacogenet. Genomics 22:219-28
164. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, et al. 2012. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin. Pharmacol. Ther. 91:734-38
165. Chen P, Lin J-J, Lu C-S, Ong C-T, Hsieh PF, et al. 2011. Carbamazepine-induced toxic effects and HLA-B?1502 screening in Taiwan. N. Engl. J. Med. 364:1126-33
166. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. 2011. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54:1433-44
167. Corless CL, Barnett CM, Heinrich MC. 2011. Gastrointestinal stromal tumours: origin and molecular oncology. Nat. Rev. Cancer 11:865-78
168. Lìevre A, Bachet J-B, Boige V, Cayre A, Le Corre D, et al. 2008. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26:374-79
169. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui C-H, et al. 2011. Clinical Pharmacogenetics ImplementationConsortium guidelines for thiopurinemethyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89:387-91
170. Innocenti F, Kroetz DL, Schuetz E,Dolan ME, Ramez J, et al. 2009. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 27:2604-14
171. Pegram MD, Pauletti G, Slamon DJ. 1998. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52:65-77
172. Druker BJ. 2009. Perspectives on the development of imatinib and the future of cancer research. Nat. Med. 15:1149-52
173. Kelloff GJ, Sigman CC. 2012. Cancer biomarkers: selecting the right drug for the right patient. Nat. Rev. Drug Discov. 11:201-14
174. Yap TA, Workman P. 2012. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu. Rev. Pharmacol. Toxicol. 52:549-73
175. Wells QS, Delaney JT, Roden DM. 2012. Genetic determinants of response to cardiovascular drugs. Curr. Opin. Cardiol. 27:253-61
176. Kelleher FC, Solomon B,McArthur GA. 2012. Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. J. Pers. Med. 2:35-49
177. Garay JP, Gray JW. 2012. Omics and therapy-a basis for precision medicine. Mol. Oncol. 6:128-39
178. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, et al. 2002. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359:1121-22
179. Mallal S, Nolan D, Witt C, Masel G, Martin AM, et al. 2002. Association between presence of HLAB ?5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-32
180. Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, et al. 2008. HLA-B?5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358:568-79
181. Saag M, Balu R, Phillips E, Brachman P, Martorell C, et al. 2008. High sensitivity of human leukocyte antigen-B?5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46:1111-18
182. Phillips EJ, Mallal SA. 2010. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 11:973-87
183. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. 2011. Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 365:2002-12
184. Johnson JA, Cavallari LH, Beitelshees AL, Lewis JP, Shuldiner AR, et al. 2011. Pharmacogenomics: application to the management of cardiovascular disease. Clin. Pharmacol. Ther. 90:519-31
185. Aithal GP,Day CP, Kesteven PJ,Daly AK. 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-19
186. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, et al. 2005. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352:2285-93
187. Wadelius M, Chen LY, Lindh JD, ErikssonN,Ghori MJR, et al. 2009. The largest prospective warfarintreated cohort supports genetic forecasting. Blood 113:784-92
188. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. 2009. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360:753-64
189. Kim M-J, Huang S-M, Meyer UA, Rahman A, Lesko LJ. 2009. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J. Clin. Pharmacol. 49:138-46
190. Finkelman BS, Gage BF, Johnson JA, Brensinger CM,Kimmel SE. 2011. Genetic warfarin dosing: tables versus algorithms. J. Am. Coll. Cardiol. 57:612-18
191. Epstein RS, Moyer TP, Aubert RE, O'Kane DJ, Xia F, et al. 2010. Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55:2804-12
192. Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, et al. 2011. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118:3163-71
193. Anderson JL,Horne BD, Stevens SM, Woller SC, Samuelson KM, et al. 2012. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125:1997-2005
194. Fareed J, Thethi I, Hoppensteadt D. 2012. Old versus new oral anticoagulants: focus on pharmacology. Annu. Rev. Pharmacol. Toxicol. 52:79-99